Correction: Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementia (JAMA Psychiatry (2017) DOI: 10.1001/jamapsychiatry.2017.3391);Association of cerebral amyloid-β Aggregation with cognitive functioning in persons without dementia

JAMA Psychiatry

Volumn 75, Issue 1, 2018, Pages 84-95

  Jansen, Willemijn J ^a   Ossenkoppele, Rik ^b,c,d,e   Tijms, Betty M ^b   Fagan, Anne M ^f   Hansson, Oskar ^g   Klunk, William E ^h   Van Der Flier, Wiesje M ^b,c   Villemagne, Victor L ⁱ   Frisoni, Giovanni B ^j,k   Fleisher, Adam S ^l,m,n   Lleó, Alberto ^o   Mintun, Mark A ^p   Wallin, Anders ^q   Engelborghs, Sebastiaan ^r   Na, Duk L ^s   Chételat, Gäel ^t   Molinuevo, José Luis ^u   Landau, Susan M ^e   Mattsson, Niklas ^g   Kornhuber, Johannes ^v   Sabri, Osama ^w   Rowe, Christopher C ^f,i   Parnetti, Lucilla ^x   Popp, Julius ^y   Fladby, Tormod ^z   Jagust, William J ^e   Aalten, Pauline ^a   Lee, Dong Young ^aa   Vandenberghe, Rik ^ab   De Oliveira, Catarina Resende ^ac   Kapaki, Elisabeth ^ad   Froelich, Lutz ^ae   Ivanoiu, Adrian ^af   Gabryelewicz, Tomasz ^ag   Verbeek, Marcel M ^ah   Sanchez Juan, Páscual ^ai   Hildebrandt, Helmut ^aj   Camus, Vincent ^ak   Zboch, Marzena ^al   Brooks, David J ^am   Drzezga, Alexander ^an   Rinne, Juha O ^ao   Newberg, Andrew ^ap   De Mendonça, Alexandre ^aq   Sarazin, Marie ^ar   Rabinovici, Gil D ^d   Madsen, Karine ^as   Kramberger, Milica G ^at   Nordberg, Agneta ^au   Mok, Vincent ^av   Mroczko, Barbara ^aw   Wolk, David A ^ax   Meyer, Philipp T ^ay   Tsolaki, Magda ^az   Scheltens, Philip ^b   Verhey, Frans R J ^a   Visser, Pieter Jelle ^a,b   Aarsland, Dag ^ba   Alcolea, Daniel ^o   Alexander, Myriam ^bb   Almdahl, Ina S ^z   Arnold, Steven E ^ax   Baldeiras, Inês ^ac   Barthel, Henryk ^w   Van Berckel, Bart N M ^c   Blennow, Kaj ^q,bc   Van Buchem, Mark A ^bd   Cavedo, Enrica ^j,be,bf   Chen, Kewei ^l   Chipi, Elena ^x   Cohen, Ann D ^h   Förster, Stefan ^bg   Fortea, Juan ^o   Frederiksen, Kristian S ^bh   Freund Levi, Yvonne ^au   Gkatzima, Olymbia ^az   Gordon, Mark Forrest ^bi   Grimmer, Timo ^bj   Hampel, Harald ^be,bf,bk   Hausner, Lucrezia ^ae   Hellwig, Sabine ^ay   Herukka, Sanna Kaisa ^bl   Johannsen, Peter ^bm   Klimkowicz Mrowiec, Aleksandra ^bn   Köhler, Sebastian ^a   Koglin, Norman ^bo   Van Laere, Koen ^bp   De Leon, Mony ^bq   Lisetti, Viviana ^x   Maier, Wolfgang ^br   Marcusson, Jan ^bs   Meulenbroek, Olga ^bt   Møllergård, Hanne M ^z   Morris, John C ^f   Nordlund, Arto ^q   Novak, Gerald P ^bu   Paraskevas, George P ^ad   Perera, Gayan ^bb,bv   Peters, Oliver ^bw   Ramakers, Inez H G B ^a   Rami, Lorena ^u   Rodríguez Rodríguez, Eloy ^ai   Roe, Catherine M ^f   Rot, Uros ^at   Rüther, Eckart ^bx   Santana, Isabel ^ac   Schröder, Johannes ^ae   Seo, Sang W ^s   Sorininen, Hilkka ^bl   Spiru, Luiza ^by   Stomrud, Erik ^g   Struyfs, Hanne ^r   Teunissen, Charlotte E ^c   Vos, Stephanie J B ^a   Van Waalwijk Van Doorn, Linda J C ^ah   Waldemar, Gunhild ^bg   Wallin, Åsa K ^g   Wiltfang, Jens ^bx   Zetterberg, Henrik ^q,bc,bz   more..

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g LUND UNIVERSITY   (Sweden)

^h UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

ⁱ AUSTIN HEALTH   (Australia)

^j IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^k UNIVERSITY OF GENEVA   (Switzerland)

^l BANNER ALZHEIMER S INSTITUTE   (United States)

^m ELI LILLY AND COMPANY   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^p AVID RADIOPHARMACEUTICALS   (United States)

^q UNIVERSITY OF GOTHENBURG   (Sweden)

^r UNIVERSITY OF ANTWERP   (Belgium)

^s Sungkyunkwan University School of Medicine   (South Korea)

^t CAEN UNIVERSITY HOSPITAL   (France)

^u HOSPITAL CLÍNIC   (Spain)

^v UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^w UNIVERSITY OF LEIPZIG   (Germany)

^x UNIVERSITY OF PERUGIA   (Italy)

^y LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^z AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^aa Seoul National University   (South Korea)

^ab UNIVERSITY OF LEUVEN   (Belgium)

^ac UNIVERSITY OF COIMBRA   (Portugal)

^ad NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^ae UNIVERSITY OF HEIDELBERG   (Germany)

^af CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^ag MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^ah RADBOUD UNIVERSITY   (Netherlands)

^ai HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^aj Bremen Ost Hospital   (Germany)

^ak Université de Tours   (France)

^al WROCLAW MEDICAL UNIVERSITY   (Poland)

^am IMPERIAL COLLEGE LONDON   (United Kingdom)

^an UNIVERSITY OF COLOGNE   (Germany)

^ao TURKU UNIVERSITY HOSPITAL   (Finland)

^ap THOMAS JEFFERSON UNIVERSITY   (United States)

^aq INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^ar CENTRE HOSPITALIER SAINTE ANNE   (France)

^as Mental Health Center Glostrup   (Denmark)

^at UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^au KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^av Lui CheWoo Institute of Innovative Medicine   (Hong Kong)

^aw MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^ax UNIVERSITY OF PENNSYLVANIA   (United States)

^ay UNIVERSITY OF FREIBURG   (Germany)

^az ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^ba STAVANGER UNIVERSITY HOSPITAL   (Norway)

^bb ROCHE PRODUCTS LTD   (United Kingdom)

^bc SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^bd LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^be PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^bf SORBONNE UNIVERSITÉ   (France)

^bg TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^bh UNIVERSITY OF COPENHAGEN   (Denmark)

^bi BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^bj TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^bk LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^bl KUOPIO UNIVERSITY HOSPITAL   (Finland)

^bm University of Copenhagen   (Denmark)

^bn JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^bo Piramal Enterprises Limited   (India)

^bp DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^bq NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^br UNIVERSITY OF BONN   (Germany)

^bs LINKÖPING UNIVERSITY   (Sweden)

^bt RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^bu JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^bv KING'S COLLEGE LONDON   (United Kingdom)

^bw GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^bx UNIVERSITY OF GÖTTINGEN   (Germany)

^by CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^bz UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; AMYLOID BETA PROTEIN;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT; COGNITION; CROSS-SECTIONAL STUDY; DEMENTIA; DIAGNOSTIC TEST ACCURACY STUDY; EDUCATIONAL STATUS; EPISODIC MEMORY; FEMALE; GENOTYPE; HUMAN; LEARNING TEST; MAJOR CLINICAL STUDY; MALE; MEMORY ASSESSMENT; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROTEIN AGGREGATION; RECEIVER OPERATING CHARACTERISTIC; SEX; VERBAL MEMORY TEST; VERBAL WORD LEARNING TEST; VERY ELDERLY; COGNITIVE DEFECT; DEMENTIA ASSESSMENT; PATHOPHYSIOLOGY; PSYCHOLOGY; REFERENCE VALUE;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; COGNITION DISORDERS; COGNITIVE DYSFUNCTION; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MEMORY, EPISODIC; MENTAL STATUS AND DEMENTIA TESTS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; REFERENCE VALUES;

EID: 85040468555     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2017.4558     Document Type: Erratum

References (28)

1. JansenWJ, Ossenkoppele R, Knol DL, et al; Amyloid Biomarker Study Group. Prevalence of cerebral amyloid pathology in persons without dementia: ameta-analysis. JAMA. 2015;313(19): 1924-1938.
2. Fagan AM, Xiong C, Jasielec MS, et al; Dominantly Inherited Alzheimer Network. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med. 2014;6(226):226ra30.
3. Jack CR Jr, Wiste HJ, Weigand SD, et al. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol. 2014;13(10):997-1005.
4. Sperling RA, Johnson KA, Doraiswamy PM, et al; AV45-A05 Study Group. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging. 2013;34(3):822-831.
5. Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957-965.
6. Burnham SC, Bourgeat P, Dor V, et al; AIBL Research Group. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. Lancet Neurol. 2016;15(10):1044-1053.
7. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275-1283.
8. Petersen RC, Wiste HJ, Weigand SD, et al. Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol. 2016;73 (1):85-92.
9. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130(pt 11): 2837-2844.
10. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29 (10):1456-1465.
11. Hedden T, Oh H, Younger AP, Patel TA. Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology. 2013; 80(14):1341-1348.
12. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
13. Mielke MM, Machulda MM, Hagen CE, et al. Influence of amyloid and APOE on cognitive performance in a late middle-aged cohort. Alzheimers Dement. 2016;12(3):281-291.
14. Rentz DM, Amariglio RE, Becker JA, et al. Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia. 2011;49(9):2776-2783.
15. Ossenkoppele R, JansenWJ, Rabinovici GD, et al; Amyloid PET Study Group. Prevalence of amyloid PET positivity in dementia syndromes: ameta-analysis. JAMA. 2015;313(19):1939-1949.
16. Jack CR Jr, Wiste HJ, Weigand SD, et al. Age, sex, and APOE ϵ4 effects on memory, brain structure, and β-amyloid across the adult life span. JAMA Neurol. 2015;72(5):511-519.
17. Wilson RS, Boyle PA, Yu L, Barnes LL, Schneider JA, Bennett DA. Life-span cognitive activity, neuropathologic burden, and cognitive aging. Neurology. 2013;81(4):314-321.
18. Vemuri P, Lesnick TG, Przybelski SA, et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain. 2015;138(Pt 3):761-771.
19. Amieva H, Mokri H, Le Goff M, et al. Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 years of cognitive decline. Brain. 2014;137(Pt 4): 1167-1175.
20. Aguirre-Acevedo DC, Lopera F, Henao E, et al. Cognitive decline in a Colombian kindred with autosomal dominant Alzheimer disease: a retrospective cohort study. JAMA Neurol. 2016;73 (4):431-438.
21. Roe CM, Fagan AM, Grant EA, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013; 80(19):1784-1791.
22. Mormino EC, Betensky RA, Hedden T, et al; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing; Harvard Aging Brain Study. Amyloid and APOE ϵ4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760-1767.
23. Lim YY, Villemagne VL, Pietrzak RH, et al; Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group. APOE ϵ4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. Neurobiol Aging. 2015;36(3): 1239-1244.
24. Seo EH, Kim SH, Park SH, Kang SH, Choo IH; Alzheimer's Disease Neuroimaging Initiative. Independent and interactive influences of the APOE genotype and beta-amyloid burden on cognitive function in mild cognitive impairment. J Korean Med Sci. 2016;31(2):286-295.
25. Yu L, Boyle PA, Leurgans S, Schneider JA, Bennett DA. Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. Neurobiol Aging. 2014;35(4):819-826.
26. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron. 1993;11(4):575-580.
27. Dowell NG, Evans SL, Tofts PS, King SL, Tabet N, Rusted JM. Structural and resting-state MRI detects regional brain differences in young and mid-age healthy APOE-e4 carriers compared with non-APOE-e4 carriers. NMR Biomed. 2016;29(5): 614-624.
28. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs13.